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Adjusting for BMI in analyses of volumetric
mammographic density and breast
cancer risk
Sue Hudson1* , Kirsti Vik Hjerkind2, Sarah Vinnicombe3, Steve Allen4, Cassia Trewin2, Giske Ursin2,
Isabel dos-Santos-Silva1 and Bianca L. De Stavola5
Abstract
Background: Fully automated assessment of mammographic density (MD), a biomarker of breast cancer risk, is
being increasingly performed in screening settings. However, data on body mass index (BMI), a confounder of the
MD–risk association, are not routinely collected at screening. We investigated whether the amount of fat in the breast,
as captured by the amount of mammographic non-dense tissue seen on the mammographic image, can be used as a
proxy for BMI when data on the latter are unavailable.
Methods: Data from a UK case control study (numbers of cases/controls: 414/685) and a Norwegian cohort study
(numbers of cases/non-cases: 657/61059), both with volumetric MD measurements (dense volume (DV), non-dense
volume (NDV) and percent density (%MD)) from screening-age women, were analysed. BMI (self-reported) and NDV
were taken as measures of adiposity. Correlations between BMI and NDV, %MD and DV were examined after
log-transformation and adjustment for age, menopausal status and parity.
Logistic regression models were fitted to the UK study, and Cox regression models to the Norwegian study, to
assess associations between MD and breast cancer risk, expressed as odds/hazard ratios per adjusted standard
deviation (OPERA). Adjustments were first made for standard risk factors except BMI (minimally adjusted models)
and then also for BMI or NDV. OPERA pooled relative risks (RRs) were estimated by fixed-effect models, and
between-study heterogeneity was assessed by the I2 statistics.
Results: BMI was positively correlated with NDV (adjusted r = 0.74 in the UK study and r = 0.72 in the Norwegian
study) and with DV (r = 0.33 and r = 0.25, respectively). Both %MD and DV were positively associated with breast
cancer risk in minimally adjusted models (pooled OPERA RR (95% confidence interval): 1.34 (1.25, 1.43) and 1.46
(1.36, 1.56), respectively; I2 = 0%, P >0.48 for both). Further adjustment for BMI or NDV strengthened the %MD–risk
association (1.51 (1.41, 1.61); I2 = 0%, P = 0.33 and 1.51 (1.41, 1.61); I2 = 0%, P = 0.32, respectively). Adjusting for BMI
or NDV marginally affected the magnitude of the DV–risk association (1.44 (1.34, 1.54); I2 = 0%, P = 0.87 and 1.49
(1.40, 1.60); I2 = 0%, P = 0.36, respectively).
Conclusions: When volumetric MD–breast cancer risk associations are investigated, NDV can be used as a measure of
adiposity when BMI data are unavailable.
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Introduction
Mammographic density captures the amount of (radio-)-
dense tissue in the breast. Mammographic density, for a
woman’s age and body mass index (BMI), is a well-estab-
lished breast cancer risk factor [1, 2]. This biomarker of risk
is being increasingly used as an intermediate phenotype in
epidemiological studies. It also offers the potential for breast
cancer prevention strategies, including screening, to be tai-
lored according to a woman’s individual risk, in combination
with other non-genetic and genetic risk factors.
Mammographic density has traditionally been assessed
as the absolute or relative amount (as percentage of the
total breast size) occupied by the dense tissue which ap-
pears on a mammographic image as white “cotton-like”
patches. Percent mammographic density (%MD) is nega-
tively correlated with BMI (reported correlation coeffi-
cients ranging between −0.41 and −0.61 [3, 4]), which
itself is a breast cancer risk factor (positively associated
with risk in post-menopausal women but negatively asso-
ciated with risk in pre-menopausal women) [5]. Therefore,
it is essential to adjust for BMI (as well as age) and any
study of mammographic percent density that fails to do so
will lead to confounded estimates of the association be-
tween percent density and risk [6].
The recent introduction of full-field digital mammog-
raphy (FFDM), paralleled by the development of fully auto-
mated digital image assessment software, has meant that
mammographic density assessment is now routinely per-
formed in many screening settings, thus providing a unique
opportunity for the conduct of large-scale studies on this
biomarker of risk. However, a common barrier to such in-
vestigations is the lack of information on a woman’s BMI as
data on this variable are rarely collected at screening.
Most of the fully automated density assessment
methods developed for FFDM attempt to estimate from
the two-dimensional images, the volume of radio-dense
tissue (DV) as well as the volume of non-dense (fat) tissue
(NDV) and the total volume of the breast (BV) which, in
Western populations, is highly correlated with NDV.
Hence, NDV, or its BV correlate, has been used as a proxy
for BMI in analyses of mammographic density and breast
cancer risk in studies where BMI data are not available [7,
8]. However, the validity of such an approach has never
been tested empirically. The aim of this study is to assess
whether NDV can be used as a proxy for BMI when asses-
sing associations between volumetric estimates of mam-
mographic density, as derived from two-dimensional
images, and breast cancer risk.
Methods
Study participants
The present analysis was conducted within two studies: a
case control study from the UK and a cohort study from
Norway.
UK study
The study methodology of the UK case control study is de-
scribed in detail elsewhere [9]. In short, cases (n = 414)
were women with newly diagnosed breast cancer at the
Royal Marsden Hospital (RMH), London, between April
2010 and July 2012. Controls (n = 685) were women
screened and found to be breast cancer-free at the Central
and East London Breast Screening Service (CELBSS) in the
same time period. The CELBSS invites women between 50
and 70 years of age for mammographic screening once
every 3 years as part of the English National Health Service
Breast Screening Programme. Women over 70 years can
optionally contact the service for a self-referred appoint-
ment every 3 years.
Data on breast cancer risk factors, including age, ethni-
city, parity, menopausal status, use of oral contraceptives,
use of hormone therapy and self-reported height and
weight, were collected by a self-administered question-
naire at the time of screening for controls and within 15.5
months of the diagnostic mammography for cases. BMI
was calculated as weight in kg/(height in m)2. Ethnicity
was categorised in accordance with the census classifica-
tion as “White”, “Black” (African or Caribbean), “Asian”
(Indian, Pakistani or Bangladeshi) and “Other” [10].
Participants underwent full-field digital mammography,
with two views (cranio-caudal (CC) and mediolateral-ob-
lique (MLO)), of both breasts. The images were taken on
Senographe DS machines (GE Healthcare, Slough, UK).
The anonymised raw images were analysed by using Vol-
para version 1.0 (Matakina Technology Limited,
Wellington, New Zealand) [11]. This algorithm provided
fully automated estimates of the volumes (all in cm3) of
the total breast (BV), non-dense (fat) tissue (NDV) and
dense (fibro-glandular) tissue (DV) separately for each one
of the four breast/view images, and percent mammo-
graphic density (%MD) was estimated as DV/BV×100.
Norwegian study
The Cancer Registry of Norway is responsible for the ad-
ministration of BreastScreen Norway (the Norwegian
Breast Cancer Screening Program). All women within a
targeted age-range of 50–69 years resident in the coun-
try are invited to undergo mammography screening
every 2 years. From August 2006 to 2014, women who
underwent mammographic screening in the nationwide
programme were asked to complete a questionnaire on a
number of standard breast cancer risk factors and a sec-
ond questionnaire on current exposure to risk factors.
Included in the present study were women who partici-
pated in BreastScreen Norway in four counties, had in-
formation on volumetric mammographic density from
their first mammographic screening between 2007 and
2014, and had completed both questionnaires. However,
for the second questionnaire on current exposures, if the
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questionnaire or certain values were missing, informa-
tion from the questionnaire completed at a previous
screening round was used (approximately 16.5%). The
cohort consisted of 61,716 women, including 657
women who were diagnosed with a first occurrence of
breast cancer during a median follow-up from date of
screening of 3.84 (interquartile range 2.08, 4.83) years.
Women with a previous diagnosis of breast cancer (n = 970),
a ductal carcinoma in situ (DCIS) diagnosis up to 6
months after the screening date (n = 224) and a bilateral
breast cancer (n = 11) were excluded.
In a similar manner to the UK study, all women had
standard two-view full-field digital mammography of
each breast with Senographe DS or Senographe Essential
machines (GE Healthcare) or MDM L50 or MDM L30
machines (Phillips). The raw images were read by Vol-
para version 1.5.0 (Volpara Health Technologies Limited,
Wellington, New Zealand) to obtain, similarly to the UK
study, volumetric estimates of BV, NDV, DV and %MD.
Ethical approval
The UK study was approved by all relevant ethics commit-
tees (Research Ethics Committees from the Royal Mars-
den Hospital, the Barts and the London NHS Trust, and
the London School of Hygiene and Tropical Medicine).
The Norwegian study was approved by the Regional
Committee for Medical and Health Research ethics in the
South-East Health Region of Norway. In the UK, partici-
pants provided written informed consent. In the Norwe-
gian study, in accordance with the Cancer Registry
Regulations, returning the questionnaire was considered
consent, and information about screening examinations
can be used for quality assurance and research if the
women have not actively opted out. About 2% of the
women attending the programme have opted out.
Statistical methods
Descriptive analysis of UK controls and the full Norwe-
gian cohort included examination of the distributions of
BMI and volumetric mammographic measurements. For
these analyses, measurements were averaged over the
four images (that is, left and right CC and MLO images).
Natural-log transformations were applied to average
%MD, DV, NDV and BMI to normalise their distribu-
tions. Scatter plots and Pearson’s correlation coefficients
were used to examine BMI associations with %MD, DV,
NDV and BV. BMI and each mammographic measure
were regressed on age at mammogram, parity and
menopausal status using linear regression (including
controls only in the UK study and the full cohort in the
Norwegian study). Pearson’s correlation coefficients be-
tween the residuals derived from these models were then
calculated (and denoted r) to allow examination of cor-
relations that are not influenced by these variables.
For the UK case control analysis, the average density
measures from the CC and MLO images from the un-
affected breasts for cases and for a randomly selected
breast for controls were used. In order to compare the
association of %MD and DV with the odds of breast
cancer, after adjusting for different sets of confounders,
three different logistic regression models were fitted
where these two exposures were first standardised as
recommended previously [12]. The resulting estimates
are referred to as OPERA ORs (“odds ratios per adjusted
standard deviation”) and are effects per residual standard
deviation of the exposure once its association with the
confounders is accounted for. Estimation requires first
fitting a linear regression model of the exposure on the
confounders and then using the standardised residuals
derived from this model as the exposure of interest in
logistic regression models that include the same con-
founders. Fifty-one cases and 38 controls (8.1% of the
study participants) were excluded from all logistic re-
gression analyses because they were missing at least one
of the variables used in the modelling.
The first (minimally adjusted) model controlled for age
(continuous), menopausal status (pre-, peri/post-) and
parity (yes/no). (Further adjustment for ethnicity, use of
exogenous hormones and the other variables listed in
Table 1 was also considered but it is not shown as it
yielded similar results.) Second, a model was fitted that
additionally adjusted for self-reported BMI. Finally, an al-
ternative model was fitted that additionally adjusted for
log-transformed NDV in place of BMI. Adjustment for
BV instead of NDV was not considered because, al-
beit this variable is highly correlated with NDV (r = 0.99;
P = 0.001), its interpretation is made more difficult by the
fact that it reflects both DV and NDV.
In the Norwegian cohort study, average density mea-
sures were based on log-transformed average values of the
CC and MLO readings from the unaffected breast for
cases and from a randomly selected breast for non-cases.
Cox regression proportional hazards models were fitted to
the cohort data, using age as the time-scale, to evaluate
the associations of (log-transformed and standardised as
described above for the UK study) %MD and DV with
breast cancer risk, expressed in terms of hazard ratios and
referred to as OPERA HRs.
Three different models were fitted as in the UK study;
the first was minimally adjusted for screening year
(categorised using 2-year intervals), menopausal status
(pre-, peri-, post-) and parity (yes/no) (further adjustment
for country of birth as a proxy for ethnicity did not affect
the findings). A second model was additionally adjusted
for BMI, and a third model was additionally adjusted for
NDV in place of BMI. In all, 10,288 participants, including
99 cases, were excluded from all three models because
they missed data for at least one of the variables listed.
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Table 1 Baseline characteristics of the participants by status in the UK and Norwegian studiesa
UK case control study Norwegian cohort study
Controls
(n = 685)
Cases
(n = 414)
Non-cases
(n = 61,059)
Cases
(n = 657)
Age at mammography
Mean (SD) 59.5 (6.6) 67.5 (12.7) 56.9 (5.74) 57.7 (5.43)
Number 679 412 61,059 657
BMIb
Mean (SD) 26.1 (5.6) 26.4 (4.9) 25.6 (4.2) 25.8 (4.1)
Number 656 368 54,345 589
Ethnicity (UK)/Country of birth (Norway), n (%)
White/Norway 520 (76.5) 370 (89.4) 56,234 (93.8) 612 (94.2)
Non-white/Outside Norway 160 (23.5) 39 (9.6) 3693 (6.2) 38 (5.8)
Missing 5 5 1132 7
Family history of BC, n (%)
No N/A N/A 45,168 (77.1) 447 (70.0)
Yes N/A N/A 13,390 (22.9) 192 (30.0)
Missing 2501 18
Menopausal statusc, n (%)
Pre- + peri-menopausal 91 (13.3) 55 (13.3) 14,776 (25.2) 141 (22.1)
Post-menopausal 591 (86.7) 358 (86.7) 43,856 (74.8) 496 (77.9)
Missing 3 1 2427 20
Parity, n (%)
Nulliparous 209 (30.9) 65 (15.9) 4946 (8.5) 57 (9.0)
Parous 467 (69.1) 343 (84.1) 53,563 (91.5) 577 (91.0)
Missing 9 6 2550 23
Age at menarche in years, n (%)
<13 271 (53.9) 159 (54.1) 16,764 (40.9) 186 (41.9)
14+ 232 (46.1) 135 (45.9) 24,202 (59.1) 258 (58.1)
Missing 14 33 4107 43
Hormone therapy use, n (%)
No 459 (68.8) 246 (63.2) 34,150 (66.2) 305 (55.6)
Yes 208 (31.2) 143 (36.8) 17,418 (33.8) 244 (44.4)
Missing 18 25 9491 108
Educational level, n (%)
None/primary school 35 (5.2) 17 (6.2)
Lower secondary 13,772 (23.3) 164 (25.9)
Secondary or higher 641 (94.8) 225 (93.8) 45,457 (76.7) 470 (74.1)
Missing 9 142 1830 23
Breastfeeding among parous women, n (%)
Yes 358 (76.7) 224 (74.7) 46,107 (99.9) 497 (100)
Missing 3 43 9929 103
Abbreviations: BC breast cancer, BMI body mass index, N/A data not available, SD standard deviation
aPercentages calculated without missing values
bBMI estimated from self-reported height and weight as weight/height2 (in kg/m2)
cPost-menopausal women defined as those who self-reported natural (cessation of menses for at least 12months) or surgical menopause, were older than 55
years, or had ever used hormone therapy. Owing to small numbers, pre-menopausal (younger than 55 years and still having regular periods) and peri-menopausal
(younger than 55 years and having irregular periods) women were combined into a single category
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Three further models were also fitted to the Norwe-
gian data using the full reproductive and lifestyle risk
factor questionnaire data collected in this study (that is,
screening year category, menopausal status, parity, age
at menopause, age at menarche, age at first birth, dur-
ation of breastfeeding, use of hormone therapy, family
history of breast cancer, education, smoking, alcohol use
and physical activity level). In the first model, BMI was
omitted; in the second model, BMI was included; in the
third model, NDV was used instead of BMI. In total,
25,833 (41.9% of the original cohort) women with miss-
ing data on any of the variables examined were excluded
to ensure that these additional models were fitted to the
same subset of women. Departure from the proportional
hazards assumption underlying each of these fitted
models was evaluated by using tests based on Schoenfeld
residuals. The Akaike information criterion (AIC) corre-
sponding to each multivariable model from the two
countries is also reported.
Similar analytical steps were followed to study the as-
sociations between BMI and breast cancer risk, and then
NDV and breast cancer risk, in both studies, in each case
adjusting for age, menopausal status and parity.
Fixed-effects models were used to obtain pooled sum-
mary OPERA relative risk (RR) estimates from the two
studies. Between-study heterogeneity was assessed by
the Q statistic and the I2 statistic [13].
In all the analyses, we considered statistical signifi-
cance (two-sided) at a P value of less than 0.05. All ana-
lyses were conducted in Stata (IC 14 for the statistical
analysis of the UK data and the meta-analysis and IC 15
for the analysis of the Norwegian data) [14].
Results
Study participants
The baseline characteristics of the participants in the
two studies are shown in Table 1. In the UK, study cases
were, on average, older than controls and more likely to
be White. Likewise, cases were slightly older at mam-
mography than non-cases in the Norwegian study. The
mean BMI was similar for UK cases and controls and
for Norwegian cases and non-cases.
Correlations between BMI and volumetric mammographic
measures
The distributions of self-reported BMI and of NDV, the
volumetric measurement that reflects the fatty tissue in
the breast, were right-skewed in the UK control group
and in the full Norwegian cohort (Fig. 1). Table 2 shows
the correlations between each volumetric measure and
BMI after adjusting for age, parity and menopausal sta-
tus. Notably, the two studies yielded very similar results.
NDV was highly positively correlated with BMI in both
the UK (r = 0.74) and in the Norwegian (r = 0.72) study.
In contrast, the correlation between DV and BMI was
weakly positive in both the UK study (r = 0.33) and the
Norwegian study (r = 0.25). Consequently, %MD was
negatively correlated with BMI in both the UK (r = −0.66)
and Norwegian (r = −0.57) studies. The correlation
between %MD and DV was only moderate after adjust-
ment for age and BMI in the UK (r = 0.33) and Norwegian
(r = 0.55) studies (data not shown). Further analyses
showed that the findings were robust after stratification by
mammographic view, age at mammography and, for the
UK study, restricting the analysis to White women (data
not shown).
Associations between adiposity measures and breast
cancer risk
There were weak positive associations between BMI and
breast cancer risk (adjusted for age, menopausal status
and parity) in both the UK (OPERA OR 1.10, 95% confi-
dence interval (CI) 0.95, 1.26) and the Norwegian
(OPERA HR 1.09, 95% CI 1.01, 1.19) studies. The
magnitude of the BMI–risk association was not modified
by menopausal status or age in either study (P > 0.30
and P > 0.10, respectively, in models that included inter-
actions with either menopausal status or age), most
likely because of the relatively small number of younger
(pre-menopausal) women in either study. There was no
evidence of an association between NDV and breast can-
cer risk adjusting for the same covariates as for BMI
(UK study OPERA OR 0.96, 95% CI 0.83, 1.11); Norwe-
gian study OPERA HR 1.01, 95% CI 0.93, 1.09).
Associations between relative and absolute volumetric
density and breast cancer risk
Figure 2 shows study-specific and pooled summary
OPERA estimates of, respectively, %MD and DV with
breast cancer risk. In both the UK and Norwegian stud-
ies, the minimally adjusted models, which exclude any
adjustment for adiposity, show a positive association be-
tween %MD and breast cancer risk with no evidence of
between-study heterogeneity (I2 = 0%; P = 0.49). Further
adjustment for BMI showed a strengthening of the posi-
tive association between %MD and breast cancer risk:
the magnitude of the pooled OPERA RR increased from
1.34 (95% CI 1.25, 1.43) to 1.51 (95% CI 1.41, 1.61) upon ad-
justment for BMI and there was no evidence of
between-study heterogeneity for the latter (I2 = 0%; P = 0.33).
Replacing BMI with NDV, as a proxy for level of adiposity,
yielded the same strength of association between %MD
and breast cancer risk with the pooled OPERA RR in-
creasing to 1.51 (95% CI 1.41, 1.61) and there was no evi-
dence of between-study heterogeneity (I2 = 0%; P = 0.33).
The association between DV and breast cancer risk was
slightly stronger than that found for %MD in the minim-
ally adjusted model (pooled OPERA RR for DV = 1.46,
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Table 2 Pearson’s correlation coefficients of mammographic measuresa with BMIa and with log NDV
Adjusted log BMI Adjusted log NDV
UK case control
study controls onlyb
Norwegian cohort
study full cohortc
UK case control
study controls onlyb
Norwegian cohort
study full cohortc
Adjusted log NDV 0.74 0.72 – –
Adjusted log %MD −0.66 −0.57 −0.80 −0.72
Adjusted log DV 0.33 0.25 0.57 0.43
Abbreviations: BMI body mass index, DV volume of mammographically dense tissue, NDV volume of mammographically non-dense tissue, %MD percent
mammographic density
DV, NDV and %MD averaged over the cranio-caudal and mediolateral-oblique views from the left and right breasts
aAll mammographic features as well as BMI were regressed on age at mammogram, parity and menopausal status and the residuals from these regressions were
used to calculate the correlation coefficients and referred to as “adjusted” measures
bn = 646 (women with missing BMI, age, parity, menopausal status or mammographic measurements were excluded and one woman with a BMI greater than 60
was also excluded)
cn = 51,427 (women with missing BMI, age, parity, menopausal status or mammographic measurements were excluded or BMI greater than 60 were excluded)
P <0.0001 in all cases
Fig. 1 Distribution of self-reported BMI and measurements of volume of mammographic non-dense tissue in the UK and Norwegian studies.
Abbreviations: BMI body mass index, NDV volume of mammographic non-dense tissue averaged over the cranio-caudal and mediolateral-oblique
views from the left and right breasts. Vertical lines represent the median and interquartile range values
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95% CI 1.36, 1.56) and there was no evidence of between-
study heterogeneity (I2 = 0%; P = 0.87). Adjusting for BMI
had little impact on the magnitude of the DV–breast can-
cer risk association (pooled OPERA RR = 1.44, 95% CI
1.34, 1.54). When BMI was replaced by NDV, the magni-
tude of the pooled OPERA RR increased only slightly to
1.49 (95% CI 1.40, 1.60) and there was no evidence of
between-study heterogeneity (I2 = 0%; P = 0.36).
The similarity of the estimated RRs for %MD and DV
when adjusted for either BMI or NDV indicates that
these measures of adiposity lead to equivalent control of
confounding. Since the models adjusted for age, meno-
pausal status, parity and NDV have the smallest AIC in
both the UK and Norwegian studies, controlling for the
NDV, when BMI is self-reported as in these datasets, ap-
pears to be (marginally) preferable.
Further analyses of the OPERA estimates in the Nor-
wegian data show that the magnitude of the associations
of %MD and DV with breast cancer risk was little chan-
ged by adjustment for additional reproductive and life-
style factors in the subset of women with information on
these variables. The addition of BMI to this expanded
model strengthened the association between %MD and
breast cancer risk; the OPERA HR increased from 1.24
(95% CI 1.13, 1.37) to 1.39 (95% CI 1.26, 1.53). Likewise,
replacing BMI with NDV to control for adiposity led to
similar estimates (OPERA HR = 1.39, 95% CI 1.27, 1.53)
though with a marginally better fitting model using AIC.
In contrast, adjustment for BMI or NDV had little effect
on the magnitude of the DV–breast cancer risk associ-
ation (Fig. 2).
Discussion
Main findings
We found that, for screening-aged women, the associ-
ation between volumetric %MD and breast cancer risk is
partly confounded by levels of adiposity and that the two
measures of adiposity available in our studies—BMI or
NDV—lead to similar adjusted estimates of association.
In contrast, when assessing the magnitude of the associ-
ation between volumetric absolute mammographic dens-
ity (that is, DV) and breast cancer risk, adjustment for
Fig. 2 Mammographic density associations with breast cancer risk with and without adjustment for adiposity in the UK and Norwegian studies.
Abbreviations: BMI body mass index, CI confidence interval, DV volume of mammographic dense tissue, NDV volume of mammographic non-dense
(fat) tissue, %MD percent mammographic density. aDV, NDV and %MD values are the average from the cranio-caudal and mediolateral-oblique views
from the unaffected breast for cases and for a randomly selected breast side for controls, log-transformed. bIn the UK study, OPERA odds ratios (ORs)
were estimated by a logistic regression. In the Norwegian cohort study, OPERA hazard ratios (HRs) were estimated by a Cox regression model in which
attained age was taken as the time scale (see Methods section). cMinimally adjusted model: analysis adjusted for age, menopausal status and parity
in the UK study; analysis adjusted for screening year, menopausal status and parity (see Methods section). dModel additionally adjusted for age at
menopause, age at menarche, age at first birth, duration of breastfeeding, use of hormone therapy, family history of breast cancer, education, smoking,
alcohol use and physical activity level
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BMI or NDV had little or no impact on the magnitude
of the association. All of these estimates of association
are expressed in terms of units per relative standard de-
viation of the exposure (that is, using the OPERA ap-
proach). This allows us to compare estimates while
adjusting for different sets of potential confounders, in
units that account for the strength of association be-
tween the confounders and the exposure of interest [12].
Both the Norwegian cohort and the UK case control
analyses found that it is important to adjust for adiposity
when the main explanatory variable is volumetric %MD,
as estimated from a two-dimensional image; otherwise,
the relationship between %MD and breast cancer risk
may appear to be weaker. Our results based on AIC sug-
gest that objectively measured NDV may offer a slightly
better proxy for adiposity than BMI when comparing the
model’s specifications in terms of goodness of fit. This
may be a consequence of the self-reported nature of the
available BMI data, and measurement error may lead to
attenuation of the adjustment. Nevertheless, it is unclear
the extent to which BMI and NDV capture the same, or
different, underlying biological entities.
After adjustment for age, parity and menopausal sta-
tus, BMI was found to be strongly positively correlated
with NDV but strongly negatively correlated with %MD.
In contrast, BMI was weakly positively correlated with
DV. The observed strong positive BMI–NDV correlation
is consistent with findings from area-based mammo-
graphic studies [4, 6, 15]. The observed weak positive
BMI–DV correlation is also in line with findings from
other volumetric density studies [16, 17] but in contrast
to those from area-based studies which consistently re-
port a negative correlation [4, 18, 19]. The correlation
between DV and %MD after adjustment for age and
BMI was not as strong (in either the UK or Norwegian
study) as that reported in area-based studies [20].
The present study found a positive, albeit weak, associ-
ation between BMI and breast cancer risk, reflecting the
predominantly peri-/post-menopausal status of the par-
ticipants, but no association between NDV and breast
cancer risk. There is little evidence for an NDV–breast
cancer association from volumetric studies to date, but a
meta-analysis of data from 13 area-based studies has re-
ported an overall inverse association between mammo-
graphic non-dense area and risk [21] albeit with
considerable between-study heterogeneity.
Strengths and limitations
Strengths of this investigation include the availability of
data from two independent studies of women of screen-
ing age. Both studies used the same objective volumetric
density assessment method, making the two datasets
comparable. In addition, the Norwegian study was
population-based and had a very large sample size and
detailed data on a wide range of potential confounding
variables collected prior to breast cancer diagnosis and
therefore was unlikely to have been affected by recall
bias. Furthermore, although other studies have assumed
that it is reasonable to used NDV as a surrogate for BMI
[7, 8], we believe that we are the first to have formally
tested this empirically.
A limitation of this investigation is that it relied on
self-reported BMI. Previous research suggests that women
tend to understate their weight and overstate their height,
particularly those who are overweight or obese [22, 23], al-
though a recent study found that women attending
BreastScreen Norway reported weight and height within 1
kg/cm of directly measured values [24]. In most
population-based screening programmes, however, it is lo-
gistically impossible to perform anthropometric measure-
ments when women attend screening. Nevertheless, it
would be informative if similar analyses were replicated
within a study sample with measured BMI.
We used the OPERA approach to allow comparison
across different exposures (that is, effects per residual
standard deviation of the exposure once its association
with the confounders is accounted for). It is argued that
this provides a fairer comparison of the different risk gra-
dients across the different models [12]. However, a com-
mon criticism of two-step approaches, such as OPERA, is
that the standard errors of the estimated coefficients are
underestimated and thus lead to a spurious increase in the
precision of the estimated effect sizes [25].
The study was restricted to women of screening age
and not generalizable to younger women. There is also
evidence that the relationship between percent body fat
and BMI is dependent upon ethnicity [26, 27], with
Asians having a higher percentage of body fat for any
given BMI compared with Caucasians [28]. The rela-
tively small number of non-White women in both stud-
ies precluded examination by ethnicity.
Finally, both studies were based on a particular volumet-
ric mammographic density assessment approach. It would
be worthwhile to examine the extent to which the present
findings can be replicated when alternative methods of as-
sessment of volumetric mammographic density are used.
Conclusions
The availability of fully automated methods to measure
mammographic density enables the integration of such
measurements within screening programme settings,
thus facilitating the conduct of large-scale studies, in-
cluding research on whether screening should be tai-
lored to a woman’s individual risk. A perceived barrier
to the conduct of such studies is the lack of information
on a woman’s BMI. This study shows that the associ-
ation between DV and breast cancer risk is not con-
founded by BMI or NDV and hence no adjustment for
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these variables is required. In contrast, the association
between volumetric %MD and risk is confounded by
level of adiposity and adjustment for either BMI or NDV
yields similar results. Adjustment for NDV may offer
some advantages over BMI as the NDV measurements
are objective, being generated by a fully automated
algorithm, and thus do not suffer from measurement er-
rors associated with self-reported BMI. Furthermore, in
most breast screening settings, it is not feasible to collect
BMI data; therefore, NDV values are potentially very
valuable because they will be automatically available for
every woman screened. Nevertheless, these findings need
to be replicated in other populations, particularly among
those with a different age and ethnic mix.
Abbreviations
%MD: Percentage mammographic density; AIC: Akaike information criterion;
BMI: Body mass index; BV: Breast volume as ascertained from a mammogram;
CC: Cranio-caudal view; CELBSS : Central and East London Breast Screening
Service; CI: Confidence interval; DV: Dense volume (that is, absolute volume
of (radio-)dense tissue seen on a mammogram); FFDM: Full-field digital
mammography; HR: Hazard ratio; MLO: Mediolateral oblique mammogram
view; NDV: Non-dense volume (that is, volume of non-dense (fat) tissue seen
on a mammogram); OPERA: Odds per adjusted standard deviation; OR: Odds
ratio; RR: Relative risk
Acknowledgments
Not applicable.
Funding
The original data collection for the UK study was supported by the DaCosta
Foundation. The funding bodies played no role in the design, collection,
analysis, or interpretation of the data; in the writing of the manuscript; or in
the decision to submit the manuscript for publication.
Availability of data and materials
The raw data were generated at the institutions named in the article. The
datasets generated and analysed during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
SH and IdSS designed the study. SA and SV recruited the UK participants. SH,
KVH and CT performed the statistical analysis with guidance from BDS. SH
wrote the first draft of the manuscript. All authors contributed to the
interpretation of the results and critically reviewed the draft of the manuscript,
read and approved the final version of the manuscript, and agreed to be
accountable for all aspects of the work in ensuring that questions related to
the accuracy or integrity of any part of the work are appropriately investigated
and resolved.
Authors’ information
SV was previously director of the Central and East London Breast Screening
Service (UK).
Ethics approval and consent to participate
See the “Ethical approval” section of this article.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Non-Communicable Disease Epidemiology, London School
of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
2Cancer Registry of Norway, Institute of Population-based Cancer Research,
Oslo, Norway. 3Division of Imaging and Technology, Ninewells Hospital
Medical School, University of Dundee, Dundee DD2 1SY, UK. 4Royal Marsden
NHS Foundation Trust, London SW3 6JJ, UK. 5Faculty of Population Health
Sciences, Institute of Child Health, University College London, London WC1N
1EH, UK.
Received: 23 June 2018 Accepted: 8 November 2018
References
1. McCormack V, dos Santos Silva I. Breast density and parenchymal patterns
as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark
Prev. 2006;15:1159–69.
2. Huo CW, Chew GL, Britt KL, Ingman WV, Henderson MA, Hopper JL,
Thompson EW. Mammographic density-a review on the current
understanding of its association with breast cancer. Breast Cancer Res Treat.
2014;144(3):479–502.
3. Soguel L, Durocher F, Tchernof A, Diorio C. Adiposity, breast density, and
breast cancer risk: epidemiological and biological considerations. Eur J
Cancer Prev. 2017;26(6):511–20.
4. Baglietto L, Krishnan K, Stone J, Apicella C, Southey MC, English DR, Hopper
JL, Giles GG. Associations of mammographic dense and nondense areas
and body mass index with risk of breast cancer. Am J Epidemiol. 2014;
179(4):475–83.
5. Bhaskaran K, Douglas I, Forbes H, dos Santos Silva I, Leon DA, Smeeth L.
Body-mass index and risk of 22 specific cancers: a population-based cohort
study of 5.24 million UK adults. Lancet. 2014;384(9945):755–65.
6. Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, Yaffe M, Minkin S.
Body size, mammographic density, and breast cancer risk. Cancer
Epidemiology Biomarkers and Prevention. 2006;15(11):2086–92.
7. Ellison-Loschmann L, McKenzie F, Highnam R, Cave A, Walker J, Jeffreys M.
Age and ethnic differences in volumetric breast density in New Zealand
women: a cross-sectional study. PLoS One. 2013;8(7):e70217.
8. van der Waal D, Emaus MJ, Bakker MF, den Heeten GJ, Karssemeijer N,
Pijnappel RM, Veldhuis WB, Verbeek AL, van Gils CH, Broeders MJ.
Geographic variation in volumetric breast density between screening
regions in the Netherlands. Eur Radiol. 2015;25(11):3328–37.
9. Eng A, Gallant Z, Shepherd J, McCormack V, Li J, Dowsett M, Vinnicombe S,
Allen S. dos-Santos-Silva I: digital mammographic density and breast cancer
risk: a case-control study of six alternative density assessment methods.
Breast cancer research : BCR. 2014;16(5):439.
10. 2011 census guidance and methodology [http://www.ons.gov.uk/ons/
guide-method/census/2011/index.html].
11. Matakina Technology Ltd.: VolparaDensity™ user manual version 1.5.11.
2014.
12. Hopper JL. Odds per adjusted standard deviation: comparing strengths of
associations for risk factors measured on different scales and across diseases
and populations. Am J Epidemiol. 2015;182(10):863–7.
13. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis.
(0277–6715 (Print)).
14. StataCorp. Stata statistical software: release 14. College Station, TX:
StataCorp LP. In. In: 14 edn; 2015.
15. Lokate M, Peeters PH, Peelen LM, Haars G, Veldhuis WB, van Gils CH:
Mammographic density and breast cancer risk: the role of the fat
surrounding the fibroglandular tissue. Breast cancer research : BCR 2011,
13(5):R103.
16. Shepherd J, Kerlikowske K, Ma L, Duewer F, Fan B, Wang J, Malkov S,
Vittinghoff E, Cummings S. Volume of mammographic density and risk of
breast cancer. Cancer Epidemiol Biomark Prev. 2011;20:1473–82.
17. Schetter SE, Hartman TJ, Liao J, Richie JP, Prokopczyk B, DuBrock C, Signori
C, Hamilton C, Demers LM, El-Bayoumy K, et al. Differential impact of body
mass index on absolute and percent breast density: implications regarding
their use as breast cancer risk biomarkers. Breast Cancer Research &
Treatment. 2014;146(2):355–63.
18. Irwin ML, Aiello EJ, McTiernan A, Bernstein L, Gilliland FD, Baumgartner RN,
Baumgartner KB, Ballard-Barbash R. Physical activity, body mass index, and
Hudson et al. Breast Cancer Research          (2018) 20:156 Page 9 of 10
mammographic density in postmenopausal breast Cancer survivors. J Clin
Oncol. 2007;25(9):1061–6.
19. Sun X, Gierach GL, Sandhu R, Williams T, Midkiff BR, Lissowska J,
Wesolowska E, Boyd NF, Johnson NB, Figueroa JD, et al. Relationship of
mammographic density and gene expression: analysis of Normal breast
tissue surrounding breast Cancer. Clin Cancer Res. 2013;19(18):4972–82.
20. Nguyen TL, Aung YK, Evans CF, Dite GS, Stone J, MacInnis RJ, Dowty JG,
Bickerstaffe A, Aujard K, Rommens JM, et al. Mammographic density defined
by higher than conventional brightness thresholds better predicts breast
cancer risk. Int J Epidemiol. 2017;46(2):652–61.
21. Pettersson A, Graff RE, Ursin G, Santos Silva ID, McCormack V, Baglietto L,
Vachon C, Bakker MF, Giles GG, Chia KS, et al. Mammographic density
phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst.
2014;106(5).
22. Stommel M, Schoenborn CA. Accuracy and usefulness of BMI measures
based on self-reported weight and height: findings from the NHANES &
NHIS 2001-2006. BMC Public Health. 2009;9(1):1–10.
23. Connor Gorber S, Tremblay M, Moher D, Gorber B. A comparison of direct
vs. self-report measures for assessing height, weight and body mass index:
a systematic review. Obesity reviews : an official journal of the International
Association for the Study of Obesity. 2007;8(4):307–26.
24. Tsuruda KM, Sagstad S, Sebuødegård S, Hofvind S. Validity and reliability of
self-reported health indicators among women attending organized
mammographic screening. Scandinavian Journal of Public Health. 0(0):
1403494817749393.
25. Arnold KF, Ellison G, Gadd SC, Textor J, Tennant P, Heppenstall A, Gilthorpe
MS. Adjustment for time-invariant and time-varying confounders in
'unexplained residuals' models for longitudinal data within a causal
framework and associated challenges. Stat Methods Med Res. 2018:
962280218756158.
26. Rush EC, Goedecke JH, Jennings C, Micklesfield L, Dugas L, Lambert EV, Plank
LD. BMI, fat and muscle differences in urban women of five ethnicities from
two countries. International journal of obesity (2005). 2007;31(8):1232–9.
27. Gurrici S, Hartriyanti Y, Hautvast JG, Deurenberg P. Differences in the
relationship between body fat and body mass index between two different
Indonesian ethnic groups: the effect of body build. Eur J Clin Nutr. 1999;
53(6):468–72.
28. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from
Caucasians and from each other in their body mass index/body fat per cent
relationship. Obesity reviews : an official journal of the International
Association for the Study of Obesity. 2002;3(3):141–6.
Hudson et al. Breast Cancer Research          (2018) 20:156 Page 10 of 10
